🔴 Crispr Therapeutics is trading 4.3% down today with no clear company-specific catalyst

Crispr Therapeutics is trading 4.3% down at $58.30, with no clear company-specific catalyst identified for the August 26, 2026 decline.

• Its latest major update, the August 3 second-quarter report, showed a narrower-than-expected loss and stronger revenue, rather than negative news.
• The move does not appear sector-led: biotech was higher, while broader indexes were only modestly weaker.
• Trading activity and volume data were unavailable, so the immediate trigger remains unclear.